- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 24.10. | ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer space | ||
| 23.10. | Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions | ||
| 23.10. | EQT buys molecular diagnostics specialist Qiagen in a €10.8B deal | ||
| 23.10. | Gilead to pay $1.3B upfront for PepStar's oral IL-23 challenger to J&J's Icotyde | ||
| 23.10. | Bolt Biotherapeutics makes inflammation play with Prana reverse merger, $120M financing | ||
| 23.10. | ESMO: Boehringer builds case for late-phase rival to Amgen's Imdelltra | ||
| 23.10. | ESMO: Zentalis already dreaming of launch for WEE1 inhibitor after 'great result' in early-stage test | ||
| 23.10. | BMS leads Pathos AI's $237M series E alongside Alzheimer's link-up | ||
| 23.10. | Chutes & Ladders-Troubled CSL enlists GSK vet Deborah Waterhouse to lead | ||
| 23.10. | ESMO: Takeda's $1.2B bet on Innovent 'absolutely' pays off with details of ADC's phase 3 win | ||
| 23.10. | Roche pays Zymeworks $55M for trispecific challenger to Amgen's Imdelltra | ||
| 23.10. | Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma's China licensing deals | ||
| 22.10. | After leak, Merck and Moderna post phase 3 cancer vaccine data early | ||
| 22.10. | Abbott to separate Nutrition business into an independent, publicly traded company | ||
| 22.10. | Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M | ||
| 22.10. | AbbVie scratches out phase 3 hidradenitis suppurativa win but falls short of expectations | ||
| 22.10. | Menarini's Stemline picks up Georgiamune preclinical cancer immunotherapy in $1.1B deal | ||
| 22.10. | Quest Diagnostics' test results system breached in yet another medtech cyberattack | ||
| 22.10. | Rebranded NodThera plans IPO to fund NLRP3 inhibitor's push toward approval | ||
| 22.10. | Roche's CEO has 'absolutely not' changed tune on Poseida despite scrapping CAR-T from the buyout | ||
| 21.10. | 'A two-way conversation with the tumor': Researchers use 'avatar' to predict immunotherapy responses | ||
| 21.10. | Astellas links up with AI Proteins in $400M computational d rugdiscovery deal | ||
| 21.10. | Amid bepirovirsen triumph, GSK quietly scraps trial of next-gen hep B therapy | ||
| 21.10. | Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches | ||
| 21.10. | 'We're getting back to stability': CBER Director Karim Mikhail shares his strategy with Fierce |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.